BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.

Here is the original post:
Teligent, Inc. Announces Third Quarter 2020 Results

Not for distribution by US newswire or in United States

Continued here:
Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants

Read the rest here:
Draft Top Tool Reviews - Go Topless! – Product Review by Mike Vaughn

More than 25 years ago, it was a patient with a port-wine stain who inspired Alster to learn more about the then-fledgling world of lasers. Alster accepted a fellowship in Boston, where her patient traveled to receive treatments. So in essence, I changed her life because I significantly lightened the birthmark to the point where she didn't need to cover it, says Alster. And she changed my life because I wouldn't have looked into lasers if it wasn't for her... I ended up opening up my own center in Washington, D.C. in 1990. And at that time it was the only freestanding laser center in the world.

Lasers and Scars

Lasers can treat many types of scars, including surgical scars, acne scars, and scars from injuries. They penetrate the epidermis to stimulate new, healthy skin cell growth. The most common lasers used in scar removal are ablative fractional carbon dioxide lasers, Nd:YAG, nonablative fractional lasers, and pulsed dye lasers.

Lasers and Hair Removal

Laser hair removal is a medical procedure that uses a concentrated beam of light to remove unwanted hair. The laser emits a light that is absorbed by the pigment (melanin) in the hair. The light energy is converted to heat, which then damages the hair follicles that produce hairs. This damage inhibits or delays future hair growth. With repeated treatments, laser hair removal can permanently reduce unwanted hair. While all hairs dont fall out immediately, they will shed within days to weeks of treatment.

But lasers arent only used for hair reduction. Low-Level Laser Therapy (LLLT) is a relatively new treatment that uses low-power lasers to stimulate hair growth. Its hypothesized that LLLT stimulates stem cells in the hair follicle and shifts the follicles in the anagen (growth) stage of the hair cycle.

How is LED different from lasers?

Commonly confused with lasers, light-emitting diodes (LED) can reduce fine lines, increase collagen production, and smooth skin by using varying color wavelengths of visible LED light. Lasers, on the other hand, often use a single wavelength, and the beam is ideal for stimulating changes that only respond to very specific wavelengths (hair removal, dark spot removal, etc.).

Can you combine lasers with other in-office treatments in the same session?

Short answer: Yes! Depending on the laser you and your dermatologist choose, you can get filler or Botox in the same treatment. Some experts will specifically recommend injectables with Fraxel within the same appointment since its considered safe and delivers a rather dramatic final result. Alster often combines non-ablative laser treatments with microneedling to amplify the effects.

Can you be too young for lasers?

When deciding whether or not to try a laser, your age shouldnt be a major deciding factor. It's more of a matter of the problem you want to fix, not how old you are. Many young people have rosacea, acne, sun spots, and sun damage all of which are treatable with lasers. Still, less-intensive therapies, such as chemical peels, are likely enough to repair young, relatively healthy skin (and are often less expensive).

Is it safe to laser your skin at home?

There are various options for at-home laser treatments that you can use safely. Typically, at-home devices have significantly lower power than those used in a medical setting, in order to reduce risks. Many lasers for wrinkles or acne are simply LED light products, like the Dr. Dennis Gross Skincare DRx SpectraLite mask. There are, however, a few at-home non-ablative fractional lasers available, like the Tria SmoothBeauty Laser.

Michelles Current Favorites

While everyones skin is different and your personal dermatologist knows whats best for you Michelle says she slathered her face with Aquaphor following a Fraxel treatment. You really do need to keep your skin moist [afterward], she says. And then it's all about sunscreen, sunscreen, sunscreen. Right now, Michelle is into Dr. Loretta Urban Antioxidant Sunscreen SPF 40, which has a slight tint.

Jennys Current Favorites

Like Michelle, Jenny used Aquaphor after getting Fraxel. She also used CeraVe Moisturizing Cream post-treatment to help speed up healing. And in order to cover up the sandpaper-like texture and small, dark dots that often arise after getting Fraxel, Jenny used Oxygenetix Oxygenating Foundation. A lot of dermatologists and plastic surgeons recommend it for people to use this when they're healing, she says. It's thicker than what I would normally use for foundation, but it gave a really seamless finish [and] got me through that week or two after [treatment].

Like many in-office treatments, lasers often come with some downtime. But good things come to those who wait: Lasers can have a huge impact on the look and health of your skin.

Original post:
The Complete Guide to Laser Treatments for Hair and Skin | The Science of Beauty Podcast | Allure - Allure

Sign Up for

Our free email newsletters

Vaccines at warp speed

Only one breakthrough truly mattered this year: the creation of a COVID-19 shot. The previous record for the fastest vaccine development, for mumps, was four years. But on Dec. 8 11 months after research began a 90-year-old British grandmother became the first person in the world to receive Pfizer's new COVID vaccine outside of a clinical study. Like Moderna's new shot, which was approved in the U.S. last week, the two-dose vaccine is about 95 percent effective and uses an entirely new type of technology. In traditional vaccines, a patient is injected with dead viral material, which triggers the body to produce antibodies. Pfizer's and Moderna's shot use a synthetic version of coronavirus genetic material that leads human cells to produce copies of the virus' outer spike proteins. Those proteins spark an immune defense. Pfizer and Moderna together hope to deliver enough doses for 20 million people by Dec. 31. "The light at the end of the tunnel is getting a little brighter," says infectious-disease expert Dr. William Schaffner.

Solving a protein puzzle

An artificial intelligence program appears to have solved one of the biggest mysteries in biology. The "protein-folding problem" is important because most biological processes such as how insulin controls blood-sugar levels or how antibodies fight coronaviruses are driven by proteins. How the strings of amino acids that make up a protein twist and fold into a 3D shape determines its function. Trying to establish how proteins get their origami-like structure can take years of lab work. But AlphaFold, an artificial intelligence program developed by the Google-owned DeepMind lab, can do it in a matter of hours with a remarkable level of accuracy. Bioinformatics professor Janet Thornton says protein-folding was "a problem that I was beginning to think would not get solved in my lifetime."

Building living 'bots

American scientists have created the world's first living robots. The millimeter-wide "xenobots" were formed by scraping live stem cells from frog embryos and leaving them to incubate. The resulting skin and heart cells were then reshaped and combined into "body forms" designed by a supercomputer to complete certain tasks walking, for example, or swimming. The pulsing heart cells serve as a miniature engine that powers xenobots until their energy reserves run out after about 10 days at present. Study co-leader Michael Levin says these "living, programmable organisms" might one day carry out tasks such as removing plaque from artery walls.

Signs of life on Venus?

Scientists have found hints that life might exist on Venus a notoriously inhospitable planet where surface temperatures hit 860 degrees Fahrenheit. Using powerful telescopes, researchers detected traces of the gas phosphine in the Venusian atmosphere. On Earth, that gas is produced by human industry and by microbial organisms that live in oxygen-free environments. Phosphine is quick to react and disappear, so something must be replenishing its supply on Venus. Researchers say it's not implausible that single-celled life might survive in the Venusian atmosphere, floating in a region where liquid water exists. Study co-author Sara Seager says the only way to confirm this theory is by "actually going to Venus."

This article was first published in the latest issue of The Week magazine. If you want to read more like it, you can try six risk-free issues of the magazine here.

More:
The big scientific breakthroughs of 2020 - The Week

VANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be assessing the use of glycosaminoglycans (GAGs) for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). GAGs are long linear polysaccharides consisting of repeating disaccharide units (i.e., two-sugar units) that participate in many biological processes, in particular, cell signalling and development, anti-coagulation and tumour progression. Their large structural diversity makes them useful in the discovery of new drugs. Heparin is a clinically useful GAG with anticoagulant properties. The use of inhaled unfractionated heparin has been shown to have anti-inflammatory and mucolytic effects with the potential to modify the progression of asthma and COPD. However, its major side effect continues to be bleeding. Therefore, there is a need for a better heparin-like molecule which is anti-inflammatory but with minimal anticoagulant effects. Lui Franciosi states, “While reviewing the existing scientific literature and searching out which GAG molecules could be useful for treating COVID-19, it makes sense to also look at their potential effects in asthma and COPD. These diseases share common inflammatory pathways which make them liable to heparin but also to current steroid therapies which also have unique side effects of their own.”

View post:
Franciosi Consulting Assessing New Potential Treatments for Asthma and COPD

Follow this link:
Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China

Press Release

View post:
Change in Number of Shares and Votes in Immunicum AB (publ)

Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK

Original post:
Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK

BERKELEY HEIGHTS, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase™ Digital 2021. The conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs.

Read more here:
Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021

– Sulanda® is Chi-Med’s first oncology drug brought to market without a partnership and the company’s second oncology drug approved in China –

View post:
Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

– exoIL-12 resulted in no local or systemic treatment-related adverse events –

Read more:
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy...

GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).

Read the rest here:
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.

Read this article:
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer

Read the original:
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab...

Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures

Go here to see the original:
BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

FARMINGTON HILLS, Mich., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, President and Chief Executive Officer, will make a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Thursday, January 7, 2021 at 11am Eastern Time.

Original post:
Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021

Dr. Louis Monti, VistaGen’s Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review Dr. Louis Monti, VistaGen’s Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review

See the rest here:
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and...

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients, "Inmunoensayo de flujo lateral para la detección cualitativa de la proteína nucleocápside del SARS-CoV-2".

Original post:
Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2...

- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response -

Read more:
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program